To access this element change to forms mode OFF
Grant Award View - GA52664
Targeting the NAD pathway as a new therapeutic strategy for high-risk...
GA ID:
GA52664
Agency:
Cancer Australia
Approval Date:
17-May-2019
Publish Date:
3-Jul-2019
Category:
Cancer
Grant Term:
20-May-2019 to 19-May-2022
Value (AUD):
$321,045.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
CA 18/19 Improved cancer control
Grant Program:
2018 Priority-driven Collaborative Cancer Research Scheme
Grant Activity:
Targeting the NAD pathway as a new therapeutic strategy for high-risk leukaemia in children
Purpose:
Rapidly dividing cancer cells can be dependent on a cellular biochemical called nicotinamide adenine dinucleotide (NAD) as an energy source. The Investigators discovered a new drug that blocks the production of NAD and has remarkably strong anti-leukaemia activity, even against the most aggressive subtypes of leukaemia. This proposal aims to develop this drug as a novel therapeutic strategy for aggressive leukaemia in children, to ultimately improve their survival and minimise the side effects of treatment.
GO ID:
GO Title:
2018 PdCCRS Project Grants for funding commencing 2019
Internal Reference ID:
2018 PdCCRS
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
No
Confidentiality - Outputs:
No
Grant Recipient Details
Recipient Name:
University of New South Wales
Recipient ABN:
57 195 873 179
Grant Recipient Location
Suburb:
Kensington
Town/City:
Sydney
Postcode:
2052
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
National
Postcode:
Multiple
Country:
AUSTRALIA